Follicum AB Information

Follicum have successfully completed the two first clinical trials with FOL-005, In the second clinical trial with the drug candidate, FOL-005, which was carried out at the Charité Hospital in Berlin, the results from the clinical study showed that at the highest dose of FOL-005, hair growth increased by an average of 7 hairs per cm2 during the study period. The study also showed that there was a marked increase in the number of hair follicles. Follicum has a new peptide class with great potential in the treatment of diabetes. During the past year, we have carried out a variety of preclinical studies that have shown that Follicum’s peptides have insulin-releasing effects that are comparable to, or even better than, existing diabetes treatments. Moreover, insulin release is potentiated with increasing glucose concentration in in vitro studies. The potential of the peptides has also been confirmed in glucose tolerance tests where they have a glucose lowering effect in experimental animals. The market for diabetes-related drugs is huge and very competitive. Therefore, we are focusing on identifying factors that can differentiate us from competitors and thereby lead to an early partnership engagement. The preclinical results demonstrate the ability of peptides to delay the onset of Type 1 diabetes in an animal model. The results further clarify that the peptide specifically distributes to the pancreas, which is beneficial for an insulin regulating drug because the pancreas is the body’s center for insulin production. The next objective in the diabetes project is to select a drug candidate by the beginning of 2019 and to begin preparations for a Phase I study planned to commence during 2020. The goal is to run a diabetes project that is attractive to global partners.